WB 1:500-1:2000; IHC 1:100-1:300; ELISA 1:20000; IF 1:50-200
Formulation
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Specificity
This antibody detects endogenous levels of PDE4B/C/D only when phosphorylated at Human:S190, Mouse:S129, Rat:S185..The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):REsFL
Purification
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Storage
-15°C to -25°C/1 year(Do not lower than -25°C)
Concentration
1 mg/ml
MW(Observed)
76kD
Modification
Phospho
Clonality
Polyclonal
Isotype
IgG
Related Products
Primary Antibodies
PDE4B/C/D Rabbit pAb
YT3628
More→
Primary Antibodies
PDE4B/C/D (Phospho Ser133/119/190) Rabbit pAb
YP0668
More→
Secondary Antibodies
Goat Anti Mouse IgG(H+L) (HRP)
RS0001
More→
Secondary Antibodies
Goat Anti Rabbit IgG(H+L) (HRP)
RS0002
More→
Primary Antibodies
β-actin (PTR2364) Mouse mAb
YM3028
More→
Primary Antibodies
GAPDH (PTR2304) Mouse mAb
YM3029
More→
Antigen&Target Information
Immunogen:
The antiserum was produced against synthesized peptide derived from human PDE4D around the phosphorylation site of Ser190/53. AA range:156-205
show all
Specificity:
This antibody detects endogenous levels of PDE4B/C/D only when phosphorylated at Human:S190, Mouse:S129, Rat:S185..The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):REsFL
This gene is a member of the type IV, cyclic AMP (cAMP)-specific, cyclic nucleotide phosphodiesterase (PDE) family. The encoded protein regulates the cellular concentrations of cyclic nucleotides and thereby play a role in signal transduction. Altered activity of this protein has been associated with schizophrenia and bipolar affective disorder. Alternative splicing and the use of alternative promoters results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Jul 2014],
show all
Function:
Alternative products:Additional isoforms seem to exist,Catalytic activity:Adenosine 3',5'-cyclic phosphate + H(2)O = adenosine 5'-phosphate.,enzyme regulation:Inhibited by rolipram.,Function:May be involved in mediating central nervous system effects of therapeutic agents ranging from antidepressants to antiasthmatic and anti-inflammatory agents.,pathway:Purine metabolism; cAMP degradation; AMP from cAMP: step 1/1.,similarity:Belongs to the cyclic nucleotide phosphodiesterase family.,tissue specificity:Expressed in brain, heart, lung and skeletal muscle.,
show all
Cellular Localization:
[Isoform PDE4B5]: Cytoplasm . Cell membrane .
show all
Tissue Expression:
Expressed in brain, heart, lung and skeletal muscle (PubMed:17519386). Expressed in white blood cells (PubMed:8392015). ; [Isoform PDE4B5]: Brain-specific isoform.